ReviewComputational and structural biotechnology journal2022
Gut microbial metabolome in inflammatory bowel disease: From association to therapeutic perspectives.
Review in Computational and structural biotechnology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Research trends and hotspots of metabolites and inflammatory bowel disease: a bibliometric analysis.Frontiers in microbiology · 2025Pooled it
- S'Wipe: user-friendly stool collection for high-throughput gut metabolomics and multi-omics.mSystems · 2026Article
- Protective effects ofFrontiers in microbiology · 2026Article
- The characteristics of gut microbiota in colorectal cancer with different microsatellite states.Frontiers in cellular and infection microbiology · 2026Article
- Integrating gut microbiota and metabolomics in pediatric inflammatory bowel disease: insights into pathogenesis and potential role of precision medicine.European journal of medical research · 2025Review
- Ergosterol-loaded brain-targeted liposomes attenuate stroke via gut microbiota-metabolite-brain axis modulation.Journal of nanobiotechnology · 2025Article
- Butyrate ameliorates ulcerative colitis through targeting STING-dependent ER stress signaling and limiting CD4Journal of inflammation (London, England) · 2025Article
- A narrative review on fecal microbiota transplantation routes in ulcerative colitis: identifying the optimal approach across key parameters.Annals of medicine and surgery (2012) · 2025Review
- Matrix Dynamics and Microbiome Crosstalk: Matrix Metalloproteinases as Key Players in Disease and Therapy.International journal of molecular sciences · 2025Review
- Treatment of Acute Ulcerative Colitis with Zinc Hyaluronate in Mice.Journal of microbiology and biotechnology · 2025Article
- Utility of Machine Learning to Characterize Gut Microbiota Dysbiosis and Its Clinical Implications in Inflammatory Bowel Disease.Journal of inflammation research · 2025Review
- Regulation of pyroptosis by natural products in ulcerative colitis: mechanisms and therapeutic potential.Frontiers in pharmacology · 2025Review
- Association study between intestinal microbiota dysbiosis in inflammatory bowel disease and the global disease burden growth trend.Frontiers in medicine · 2025Article
- Bile Acids in Inflammatory Bowel Disease: From Pathophysiology to Treatment.Biomedicines · 2024Review
- Water-soluble garlic polysaccharide (WSGP) improves ulcerative volitis by modulating the intestinal barrier and intestinal flora metabolites.Scientific reports · 2024Article
- Altered mucosal bacteria and metabolomics in patients with Peutz-Jeghers syndrome.Gut pathogens · 2024Article
- Article
- Article
- Inflammation and Organic Cation Transporters Novel (OCTNs).Biomolecules · 2024Review
- Porphyromonas gingivalis aggravates colitis via a gut microbiota-linoleic acid metabolism-Th17/Treg cell balance axis.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC), is a set of clinically chronic, relapsing gastrointestinal inflammatory disease and lacks of an absolute cure. Although the precise etiology is unknown, developments in high-throughput microbial genomic sequencing significantly illuminate the changes in the intestinal microbial structure and functions in patients with IBD. The application of microbial metabolomics suggests that the microbiota can influence IBD pathogenesis by producing metabolites, which are implicated as crucial mediators of host-microbial crosstalk. This review aims to elaborate the current knowledge of perturbations of the microbiome-metabolome interface in IBD with description of altered composition and metabolite profiles of gut microbiota. We emphasized and elaborated recent findings of several potentially protective metabolite classes in IBD, including fatty acids, amino acids and derivatives and bile acids. This article will facilitate a deeper understanding of the new therapeutic approach for IBD by applying metabolome-based adjunctive treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.